Blog
About

  • Record: found
  • Abstract: found
  • Article: not found

A Big Bang model of human colorectal tumor growth

Read this article at

ScienceOpenPublisherPMC
Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      What happens in the early, still undetectable human malignancy is unknown because direct observations are impractical. Here we present and validate a “Big Bang” model, whereby tumors grow predominantly as a single expansion producing numerous intermixed sub-clones that are not subject to stringent selection, and where both public (clonal) and most detectable private (subclonal) alterations arise early during growth. Genomic profiling of 349 individual glands from 15 colorectal tumors revealed the absence of selective sweeps, uniformly high intra-tumor heterogeneity (ITH), and sub-clone mixing in distant regions, as postulated by our model. We also verified the prediction that most detectable ITH originates from early private alterations, and not from later clonal expansions, thus exposing the profile of the primordial tumor. Moreover, some tumors appear born-to-be-bad, with sub-clone mixing indicative of early malignant potential. This new model provides a quantitative framework to interpret tumor growth dynamics and the origins of ITH with significant clinical implications.

      Related collections

      Most cited references 64

      • Record: found
      • Abstract: found
      • Article: not found
      Is Open Access

      Comprehensive Molecular Characterization of Human Colon and Rectal Cancer

      Summary To characterize somatic alterations in colorectal carcinoma (CRC), we conducted genome-scale analysis of 276 samples, analyzing exome sequence, DNA copy number, promoter methylation, mRNA and microRNA expression. A subset (97) underwent low-depth-of-coverage whole-genome sequencing. 16% of CRC have hypermutation, three quarters of which have the expected high microsatellite instability (MSI), usually with hypermethylation and MLH1 silencing, but one quarter has somatic mismatch repair gene mutations. Excluding hypermutated cancers, colon and rectum cancers have remarkably similar patterns of genomic alteration. Twenty-four genes are significantly mutated. In addition to the expected APC, TP53, SMAD4, PIK3CA and KRAS mutations, we found frequent mutations in ARID1A, SOX9, and FAM123B/WTX. Recurrent copy number alterations include potentially drug-targetable amplifications of ERBB2 and newly discovered amplification of IGF2. Recurrent chromosomal translocations include fusion of NAV2 and WNT pathway member TCF7L1. Integrative analyses suggest new markers for aggressive CRC and important role for MYC-directed transcriptional activation and repression.
        Bookmark
        • Record: found
        • Abstract: found
        • Article: not found

        Cancer genome landscapes.

        Over the past decade, comprehensive sequencing efforts have revealed the genomic landscapes of common forms of human cancer. For most cancer types, this landscape consists of a small number of "mountains" (genes altered in a high percentage of tumors) and a much larger number of "hills" (genes altered infrequently). To date, these studies have revealed ~140 genes that, when altered by intragenic mutations, can promote or "drive" tumorigenesis. A typical tumor contains two to eight of these "driver gene" mutations; the remaining mutations are passengers that confer no selective growth advantage. Driver genes can be classified into 12 signaling pathways that regulate three core cellular processes: cell fate, cell survival, and genome maintenance. A better understanding of these pathways is one of the most pressing needs in basic cancer research. Even now, however, our knowledge of cancer genomes is sufficient to guide the development of more effective approaches for reducing cancer morbidity and mortality.
          Bookmark
          • Record: found
          • Abstract: found
          • Article: found

          Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

          Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples. To examine intratumor heterogeneity, we performed exome sequencing, chromosome aberration analysis, and ploidy profiling on multiple spatially separated samples obtained from primary renal carcinomas and associated metastatic sites. We characterized the consequences of intratumor heterogeneity using immunohistochemical analysis, mutation functional analysis, and profiling of messenger RNA expression. Phylogenetic reconstruction revealed branched evolutionary tumor growth, with 63 to 69% of all somatic mutations not detectable across every tumor region. Intratumor heterogeneity was observed for a mutation within an autoinhibitory domain of the mammalian target of rapamycin (mTOR) kinase, correlating with S6 and 4EBP phosphorylation in vivo and constitutive activation of mTOR kinase activity in vitro. Mutational intratumor heterogeneity was seen for multiple tumor-suppressor genes converging on loss of function; SETD2, PTEN, and KDM5C underwent multiple distinct and spatially separated inactivating mutations within a single tumor, suggesting convergent phenotypic evolution. Gene-expression signatures of good and poor prognosis were detected in different regions of the same tumor. Allelic composition and ploidy profiling analysis revealed extensive intratumor heterogeneity, with 26 of 30 tumor samples from four tumors harboring divergent allelic-imbalance profiles and with ploidy heterogeneity in two of four tumors. Intratumor heterogeneity can lead to underestimation of the tumor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges to personalized-medicine and biomarker development. Intratumor heterogeneity, associated with heterogeneous protein function, may foster tumor adaptation and therapeutic failure through Darwinian selection. (Funded by the Medical Research Council and others.).
            Bookmark

            Author and article information

            Affiliations
            [1 ] Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA USA
            [2 ] Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, CA USA
            [3 ] Department of Pathology, CHA University, Seongnam-si, Gyeonggi-do, South Korea
            [4 ] Center for Evolution and Cancer, University of California, San Francisco, San Francisco, CA USA
            [5 ] Centre for Tumor Biology, Barts Cancer Institute, Queen Mary University of London, London, UK
            Author notes
            [6]

            Present addresses: Division of Molecular Pathology, Institute of Cancer Research, London, UK (A.S); Department of Medicine, Stanford University, Stanford, CA, USA (Z.M, C.C); Department of Genetics, Stanford University, Stanford, CA, USA (Z.M, C.C)

            Correspondence should be addressed to: Darryl Shibata ( dshibata@ 123456usc.edu ) or Christina Curtis ( cncurtis@ 123456stanford.edu )
            Journal
            9216904
            2419
            Nat Genet
            Nat. Genet.
            Nature genetics
            1061-4036
            1546-1718
            26 June 2015
            09 February 2015
            March 2015
            19 September 2015
            : 47
            : 3
            : 209-216
            25665006 4575589 10.1038/ng.3214 NIHMS655882
            Categories
            Article

            Genetics

            Comments

            Comment on this article